XOMA Co. (NASDAQ:XOMA) Short Interest Up 23.4% in December

by · The Markets Daily

XOMA Co. (NASDAQ:XOMA – Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 139,000 shares, an increase of 23.4% from the November 30th total of 112,600 shares. Based on an average daily volume of 29,100 shares, the short-interest ratio is presently 4.8 days.

Wall Street Analyst Weigh In

XOMA has been the subject of several analyst reports. StockNews.com cut XOMA from a “hold” rating to a “sell” rating in a report on Friday. HC Wainwright restated a “buy” rating and issued a $123.00 target price on shares of XOMA in a report on Friday, December 13th.

Get Our Latest Stock Analysis on XOMA

XOMA Stock Down 0.8 %

Shares of NASDAQ:XOMA opened at $26.09 on Tuesday. XOMA has a 1 year low of $18.57 and a 1 year high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The stock’s 50-day moving average is $29.76 and its 200 day moving average is $27.87. The company has a market cap of $307.42 million, a PE ratio of -7.50 and a beta of 0.88.

Insider Activity at XOMA

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares in the company, valued at $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 7.20% of the stock is owned by insiders.

Hedge Funds Weigh In On XOMA

A number of hedge funds and other institutional investors have recently made changes to their positions in XOMA. BNP Paribas Financial Markets boosted its holdings in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares in the last quarter. Geode Capital Management LLC increased its position in shares of XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after buying an additional 1,138 shares during the period. Rhumbline Advisers raised its stake in XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares in the last quarter. State Street Corp lifted its holdings in XOMA by 1.2% in the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after buying an additional 1,754 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after acquiring an additional 1,968 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

About XOMA

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

Recommended Stories